Dräger makes changes to Executive Board

Carla Kriwet will take responsibility for marketing and sales on 1 January 2011

The Supervisory Board of Drägerwerk Verwaltungs has appointed Dr Carla Kriwet as a new Executive Board member, who will take responsibility for marketing and sales on 1 January 2011.

Kriwet currently works for Linde Group as head of Healthcare Europe for the Division Hospital Care and Homecare in Central and Northern Europe.



Dr Dieter Pruss, currently responsible for marketing and sales for the safety division on the Executive Board, will leave the company at his own request on 31 December, 2010, to take on new challenges. 


You may also like

Personal Protection

Draeger introduces X-plore 8000 powered air purifying respirator

To help workers in the pharmaceutical sector breathe easy in harsh environments

DRAEGER OFFERS FREE COPIES OF NEW DRÄGERTUBE HANDBOOK

<p>Draeger is offering a free copy of the new DraegerTubes & CMS-Handbook to anyone with a need for short term gas detection. Available whilst stocks last, this 15th edition is packed with the latest information on more than 350 DraegerTubes and represents a definitive guide to the selection and use of short term tubes in line with current legislation.</p>

Easy infra-red upgrade and longer sensor life with explosion-proof Draeger Sensor IR

<p>Upgrading to infra-red technology has never been easier, or more cost effective, than with the longer-life, explosion-proof Draeger Sensor IR. </p>
Sustainability

Explosion-proof transmitter from Draeger

<p>Draeger Safety has launched the Draeger PIR 3000, a smart explosion proof infra-red gas transmitter that the company says ensures reliable detection of combustible gases and vapours.</p>
Regulatory

Standard proposed to clarify endotoxin testing for single-use systems

The guide will address variability when assessing bacterial endotoxins on large-scale pharmaceutical equipment
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Subscribe now